{"changeSha256":"ef83d025acacaf9716e117d1455d46c4974f8a312fca06bc0cabd45d54052d30","changedAt":"2026-11-14","changedFields":[{"after":"FDA-approved as Byetta, Bydureon and generic exenatide","before":"U.S. label record","field":"Status"},{"after":"A GLP-1 receptor agonist first approved by FDA as Byetta in 2005 to improve blood-sugar control in adults with type 2 diabetes.","before":"A GLP-1 receptor agonist. This profile cites a U.S. label record.","field":"Profile summary"},{"after":"Randomized trials described in the label show lower HbA1c than placebo. A large outcomes trial of a longer-acting exenatide product did not show a reduction in cardiovascular events. In November 2026 FDA determined that Byetta was not withdrawn from sale for safety or effectiveness reasons.","before":"The cited DailyMed label identifies Exenatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.","field":"Evidence note"},{"after":"Byetta, Bydureon","before":"None recorded","field":"Related names"},{"after":"dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17, fda-drugs-nda021773-2005-04-28-80405b2e0c23, fda-drugs-nda022200-2012-01-27-454d1777c87f, fda-drugs-nda209210-2017-10-20-473b81562789, fda-drugs-anda206697-2024-11-19-5725057d6a94, federal-register-2026-23141-024f888bd7b4, journal-pmid-28910237","before":"dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17","field":"Cited source records"},{"after":"U.S. National Library of Medicine [sources: dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17]; U.S. Food and Drug Administration [sources: fda-drugs-nda021773-2005-04-28-80405b2e0c23, federal-register-2026-23141-024f888bd7b4]","before":"U.S. National Library of Medicine [sources: dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17]","field":"Named organizations"},{"after":"name: dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17; aliases: dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17, fda-drugs-nda021773-2005-04-28-80405b2e0c23, fda-drugs-nda022200-2012-01-27-454d1777c87f; category: dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17; status: dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17, fda-drugs-nda021773-2005-04-28-80405b2e0c23, fda-drugs-nda022200-2012-01-27-454d1777c87f, fda-drugs-nda209210-2017-10-20-473b81562789, fda-drugs-anda206697-2024-11-19-5725057d6a94; summary: dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17, fda-drugs-nda021773-2005-04-28-80405b2e0c23; evidenceNote: dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17, journal-pmid-28910237, federal-register-2026-23141-024f888bd7b4","before":"name: dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17; aliases: dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17; category: dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17; status: dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17; summary: dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17; evidenceNote: dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/exenatide/versions/3/","version":3},"id":"profile:exenatide:v3","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-status-changed","notice":"We added a plain-language reader guide with cited answers, re-checked the generic exenatide label, added the Drugs@FDA approval records and the EXSCEL outcomes trial, and added FDA’s November 13, 2026 determination that Byetta was not withdrawn from sale for safety or effectiveness reasons.","peptideSlugs":["exenatide"],"previousChangeEvent":{"path":"/corrections/v1/profiles/exenatide/v2.json","sha256":"cc5eaa811978a9c8bfd60a9866552a22f00a3ec285a3aa49f0870dc3c9341b5a"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/exenatide/versions/2/","version":2},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17","name":"DailyMed · U.S. National Library of Medicine","sourceClass":"A","title":"Exenatide injection · SPL version 17 · published 2026-06-30","url":"https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=e6cb5c8f-e97f-4a6a-95a4-939fd2393949&version=17","verifiedAt":"2026-07-22"},{"id":"fda-drugs-nda021773-2005-04-28-80405b2e0c23","name":"Drugs@FDA via openFDA","sourceClass":"A","title":"Drugs@FDA application NDA021773 · original submission status AP · 2005-04-28 · dataset 2026-08-13","url":"https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA021773%22&limit=1","verifiedAt":"2026-08-14"},{"id":"federal-register-2026-23141-024f888bd7b4","name":"Federal Register via GovInfo","sourceClass":"A","title":"Federal Register notice 2026-23141 · published 2026-11-13 · Determination That DIBENZYLINE (Phenoxybenzamine Hydrochloride) Oral Capsule, 10 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness","url":"https://www.govinfo.gov/content/pkg/FR-2026-11-13/pdf/2026-23141.pdf","verifiedAt":"2026-11-14"}],"subject":{"slug":"exenatide","type":"profile"}}
